In CML patients treated with allogeneic stem cell transplantation, achievement of molecular
remission (MR), defined as undetectable BCR–ABL transcripts by nested RT-PCR, is …

Purpose In the era of molecular therapy of chronic myelogenous leukemia (CML) applying
BCR-ABL tyrosine kinase inhibitors, the usefulness of molecular end points, in particular …

BACKGROUND AND OBJECTIVES: Imatinib mesylate induces a complete cytogenetic
response (CCR) in many patients with chronic myeloid leukemia (CML). However, the …

Background Monitoring minimal residual disease (MRD) by real-time quantitative
polymerase chain reaction (RT-PCR) in chronic myeloid leukemia (CML) patients is …

Imatinib induces a high complete cytogenetic response (CCR) rate in relapsed chronic
myelogenous leukemia. By analyzing minimal residual disease (MRD) under the levels of …

Residual disease in chronic myeloid leukemia patients may be assessed by various
molecular methods. After imatinib treatment a significant proportion of patients achieve …

Elsewhere in this issue of the journal Verma and colleagues [1] report a case in which a
complete molecular response (CMR) induced by imatinib treatment was sustained for at …

Following the achievement of deep molecular response on tyrosine kinase inhibitors (TKIs),
approximately half of patients with chronic myeloid leukemia (CML) can discontinue TKI and …

After 5 years of imatinib treatment 40–50% of chronic myeloid leukaemia (CML) patients will
have stable undetectable BCR-ABL by real-time quantitative RT-PCR (RQ-PCR) using strict …

Abstract Abstract 859 Background Imatinib (IM) has greatly improved survival rates in
chronic myeloid leukemia*(* CML). However, all patients (pts) must continue treatment for an …